PRINCETON, N.J. - Drug developer Pharmasset Inc. said Thursday its fiscal 2007 third-quarter loss widened on higher expenses.
The company lost $7.1 million, or 40 cents per share, compared with a loss of $4.4 million, or 42 cents per share. Revenue fell to $464,291 from $513,784
Expenses rose to $7.1 million from $5 million, primarily from clinical trial expenses for the company's hepatitis B treatment candidate clevudine, which is in a Phase III clinical trial.read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment